Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Cash & Current Investments (2023 - 2025)

Zenas BioPharma has reported Cash & Current Investments over the past 3 years, most recently at $343.2 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $343.2 million for Q4 2025, up 7.3% from a year ago — trailing twelve months through Dec 2025 was $343.2 million (up 7.3% YoY), and the annual figure for FY2025 was $343.2 million, up 7.3%.
  • Cash & Current Investments for Q4 2025 was $343.2 million at Zenas BioPharma, up from $290.9 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for ZBIO hit a ceiling of $430.0 million in Q1 2025 and a floor of $37.2 million in Q1 2024.
  • Median Cash & Current Investments over the past 3 years was $282.1 million (2025), compared with a mean of $236.8 million.
  • Peak annual rise in Cash & Current Investments hit 1054.74% in 2025, while the deepest fall reached 19.23% in 2025.
  • Zenas BioPharma's Cash & Current Investments stood at $56.9 million in 2023, then soared by 462.52% to $319.8 million in 2024, then grew by 7.3% to $343.2 million in 2025.
  • The last three reported values for Cash & Current Investments were $343.2 million (Q4 2025), $290.9 million (Q3 2025), and $273.3 million (Q2 2025) per Business Quant data.